TAmiRNA is a biotech company focused on the discovery and validation of microRNA biomarkers, which are crucial for developing innovative diagnostic tools aimed at improving patient outcomes, particularly in age-associated diseases. Their technology leverages microRNA signatures—combinations of specific microRNA biomarkers—alongside artificial intelligence algorithms to create actionable diagnostic solutions. This approach allows for a personalized understanding of diseases such as osteoporosis, cardiovascular disease, and liver disease, enabling better diagnosis and treatment strategies tailored to individual patient profiles.

The company operates a fully equipped research and development laboratory that employs advanced techniques for high-throughput screening of microRNA levels across various biological samples, including blood and tissues. TAmiRNA has developed specific tests, such as the osteomiR® test for predicting fracture risk in post-menopausal women and the thrombomiR® test for assessing platelet function. These tests aim to facilitate early diagnosis and treatment of serious conditions, thereby enhancing patient stability and quality of life as they age. Additionally, TAmiRNA is committed to expanding its product pipeline through collaborations and in-licensing opportunities, ensuring continuous innovation in the field of precision medicine.

Austria

At TAmiRNA we drive innovation through microRNA and RNAi technology to solve unmet clinical needs. Circulating microRNAs are novel minimal-invasive biomarkers that fulfil the requirements of valuable markers. TAmiRNA excels in the identification and development of microRNA biomarkers for diagnosis and prediction of disease and treatment response with a special focus on musculoskeletal, cardiovascular and metabolic diseases. TAmiRNA is a biotech R&D company based in Vienna, Austria.

---- Privacy Policy and Imprint can be accessed by clicking "Contact us" ----

TAmiRNA

Company Details